Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with TCG GreenChem, Inc. to manufacture Ropidoxuridine, its lead clinical sensitizer drug candidate. This agreement aims to facilitate the formulation of Ropidoxuridine for clinical trials targeting brain tumors, sarcomas, and pancreatic cancers. The FDA has granted orphan-drug designation for Ropidoxuridine in glioblastoma treatment. The agreement also includes process research and optimization to enhance drug development. The market for radiation sensitizers is projected to exceed $4.0 billion due to a growing patient base.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has received patents in the U.S. and Hong Kong for its HDAC inhibitor technology, aimed at enhancing radiation therapy outcomes for cancer patients. This innovation targets over 800,000 U.S. patients undergoing radiation, with a projected market exceeding $4 billion annually. The company is focused on building its drug candidate portfolio to improve patient quality of life and treatment efficacy.
CEO Anatoly Dritschilo emphasized the goal of being at the forefront of cancer treatment advancements with selective HDAC6 inhibitors.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced the successful closing of its initial public offering (IPO) on September 6, 2022. The company sold 1,225,888 units at a public offering price of $8.125 per unit, raising approximately $9,960,340 before expenses. Each unit comprises one share of common stock and a warrant for one additional share, exercised at $0.01 each. The stock began trading on the Nasdaq on August 31, 2022. Boustead Securities, LLC acted as lead underwriter for the offering.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has commenced trading on The Nasdaq Capital Market. The company focuses on developing sensitizers to enhance the efficacy of radiation therapy for cancer patients while minimizing side effects. Their lead product candidate, Ropidoxuridine, has completed a Phase I clinical trial. Shuttle Pharma aims to address serious needs in treating brain tumors, sarcomas, and pancreatic cancers. The company is positioned to progress its innovative therapy pipeline and deliver new treatments for patients lacking effective options.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has priced its initial public offering (IPO) at $8.125 per unit, raising gross proceeds of $9,960,340. The offering consists of 1,225,888 units, each including one share of common stock and a warrant to purchase an additional share at $0.01. The company's common stock is set to begin trading on the Nasdaq Capital Market on August 31, 2022. Boustead Securities, LLC is the lead underwriter for the offering, which is expected to close on September 2, 2022, subject to customary conditions.